More Stories






News 12 senior reporter Tara Rosenblum got a rare look inside Regeneron and its race to develop the next generation of medicine. Rosenblum sat down exclusively with Dr. George Yancopoulos, cofounder, president and chief scientific officer of Regeneron to discuss the latest scientific breakthroughs.
"We're using now these new kinds of medicines to actually change or give back broken or missing genes," says Yancopoulos.
He also discussed one of the company's newest breakthroughs: a gene therapy for children born with a rare form of genetic deafness. "This gene therapy in more than half the children restored normal hearing. It's really life-changing," says Yancopoulos. And the innovations don't stop there. "We've already announced some exciting early data that we've had where we can co-treat people with weight loss drugs, but also with muscle preservation agents that we've invented here that can stave off much of the muscle loss," he says. His work has also taken him from the lab to the White House. In April, Yancopoulos joined President Donald Trump as Regeneron announced a new drug-pricing agreement aimed at lowering costs for U.S. patients. Back at home, all of this momentum comes as Regeneron continues a multibillion-dollar expansion of its sprawling Tarrytown campus.
Four decades into a career spent trying to solve medicine's hardest problems, Yancopoulos says he feels like he is "just getting started."